Brookline Capital Markets Estimates Imunon FY2026 Earnings

Imunon, Inc. (NASDAQ:IMNN – Free Report) – Stock analysts at Brookline Capital Markets lifted their FY2026 EPS estimates for Imunon in a note issued to investors on Friday, November 13th. Brookline Capital Markets analyst K. Dolliver now forecasts that the company will earn ($2.74) per share for the year, up from their prior estimate of ($2.89). The consensus estimate for Imunon’s current full-year earnings is ($2.68) per share. Brookline Capital Markets also issued estimates for Imunon’s Q4 2026 earnings at ($0.73) EPS, Q1 2027 earnings at ($0.69) EPS, Q2 2027 earnings at ($0.67) EPS, Q3 2027 earnings at ($0.67) EPS, Q4 2027 earnings at ($0.65) EPS and FY2027 earnings at ($2.67) EPS.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Imunon in a research note on Thursday, October 15th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $10.00.

Check Out Our Latest Analysis on IMNN

Imunon Stock Down 5.6%

IMNN stock opened at $0.59 on Tuesday. The company has a current ratio of 1.82, a quick ratio of 1.82 and a debt-to-equity ratio of 2.86. The firm has a 50 day moving average price of $1.13 and a 200-day moving average price of $2.09. Imunon has a 52-week low of $0.49 and a 52-week high of $4.35.

Imunon (NASDAQ:IMNN – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.09).

Imunon Company Profile

(Get Free Report)

Imunon, Inc. is a clinical-stage biotechnology company developing treatments for cancer. Formerly known as Celsion Corporation, the company adopted the Imunon name in 2022 and is based in Lawrenceville, New Jersey. Its lead candidate, IMNN-001 (formerly GEN-1), is an investigational DNA-based immunotherapy designed to prompt local production of interleukin-12, a protein that can stimulate an immune response against tumors. Imunon is studying the treatment in combination with chemotherapy for newly diagnosed advanced ovarian cancer.

Further Reading

Earnings History and Estimates for Imunon (NASDAQ:IMNN)

Receive News & Ratings for Imunon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imunon and related companies with MarketBeat.com's FREE daily email newsletter.